10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

PYCRL Blocking Peptide (C-term)

Synthetic peptide
Catalog # BP21368b

Specification

PYCRL Blocking Peptide (C-term) - Product Information

Primary Accession Q53H96

PYCRL Blocking Peptide (C-term) - Additional Information

Gene ID 65263

Other Names
Pyrroline-5-carboxylate reductase 3, P5C reductase 3, P5CR 3, Pyrroline-5-carboxylate reductase-like protein, PYCRL

Target/Specificity
The synthetic peptide sequence is selected from aa 221-235 of HUMAN PYCRL

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PYCRL Blocking Peptide (C-term) - Protein Information

Name PYCR3 (HGNC:25846)

Function
Oxidoreductase that catalyzes the last step in proline biosynthesis, which corresponds to the reduction of pyrroline-5- carboxylate (P5C) to L-proline using NAD(P)H (PubMed:23024808, PubMed:36414121). Proline is synthesized from either glutamate or ornithine; both are converted to P5C, and then to proline via pyrroline-5-carboxylate reductases (PYCRs) (PubMed:23024808). PYCR3 is exclusively linked to the biosynthesis of proline from ornithine (PubMed:23024808).

Cellular Location
Cytoplasm.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

PYCRL Blocking Peptide (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

PYCRL Blocking Peptide (C-term) - Images

PYCRL Blocking Peptide (C-term) - References

Ota T.,et al.Nat. Genet. 36:40-45(2004).
Nusbaum C.,et al.Nature 439:331-335(2006).
Suzuki Y.,et al.Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
Burkard T.R.,et al.BMC Syst. Biol. 5:17-17(2011).